Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer. (Q50039396)

23 February 2018

title

Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer. (English)

1 reference

23 February 2018

author name string

Lijun Mo

1

1 reference

23 February 2018

Qianmei Chen

2

1 reference

23 February 2018

Xinji Zhang

3

1 reference

23 February 2018

Xiaojun Shi

4

1 reference

23 February 2018

Lili Wei

5

1 reference

23 February 2018

Dianpeng Zheng

6

1 reference

23 February 2018

Hongwei Li

7

1 reference

23 February 2018

Jimin Gao

8

1 reference

23 February 2018

Jinlong Li

9

1 reference

23 February 2018

Zhiming Hu

10

1 reference

23 February 2018

language of work or name

English

0 references

publication date

15 September 2017

1 reference

23 February 2018

published in

Vaccine

1 reference

23 February 2018

volume

35

1 reference

23 February 2018

page(s)

5932-5938

1 reference

23 February 2018

issue

43

1 reference

23 February 2018

cites work

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

A novel therapeutic vaccine of GM-CSF/TNFalpha surface-modified RM-1 cells against the orthotopic prostatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Regulatory T cells: key controllers of immunologic self-tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

FOXP3+ regulatory T cells in the human immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Roles of regulatory T cells in cancer immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Differential effects of costimulatory pathway modulation on corneal allograft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Regulatory T cells in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Role of plasmacytoid dendritic cells and inducible costimulator-positive regulatory T cells in the immunosuppression microenvironment of gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Differences in tumor regulatory T-cell localization and activation status impact patient outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

A distinct role for ICOS-mediated co-stimulatory signaling in CD4+ and CD8+ T cell subsets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.08.093

10.1016/J.VACCINE.2017.08.093

7 January 2021

Identifiers

DOI

1 reference

23 February 2018

PubMed ID

28923424

1 reference

23 February 2018